Effects of pituitary hormones on the prostate

Citation
E. Reiter et al., Effects of pituitary hormones on the prostate, PROSTATE, 38(2), 1999, pp. 159-165
Citations number
69
Categorie Soggetti
Urology & Nephrology","da verificare
Journal title
PROSTATE
ISSN journal
02704137 → ACNP
Volume
38
Issue
2
Year of publication
1999
Pages
159 - 165
Database
ISI
SICI code
0270-4137(19990201)38:2<159:EOPHOT>2.0.ZU;2-3
Abstract
BACKGROUND. Although essential, androgens alone are not sufficient to induc e normal growth and functionality of the prostate. Nonandrogenic hormones m ust also be involved in the proliferation of the prostate cancer cells whic h do not respond to antiandrogenic therapy and which thus become androgen-i ndependent. Prolactin, but also growth hormone and luteinizing hormone, are potentially able to act on both normal and abnormal prostatic cells. METHODS. In this review we summarize data from the literature concerning th e physiological and pathological implications of prolactin, growth hormone, and luteinizing hormone on the prostate. RESULTS. In rodent prostates, prolactin and growth hormone can induce a var iety of effects independently of androgens (e.g., transactivation of certai n genes, or synthesis of the major secretion products). Moreover, hyperprol actinemia is responsible for inflammation and dysplasia of the gland, while growth hormone promotes the development of prostate tumors in vivo in the mouse and rat. Growth hormone acts on the gland directly, through prostatic growth hormone receptors, and/or indirectly via the stimulation of insulin -like growth factor-I (IGF-I) synthesis in the liver. Luteinizing hormone r eceptor is expressed in rat and human prostates. Luteinizing hormone increa ses the amount of various transcripts in the rat prostate through an androg en-independent pathway. CONCLUSIONS. Prolactin, growth hormone, and luteinizing hormone, alone or s ynergistically with androgens, play physiologically significant roles in th e normal prostate. The involvement of these hormones in the development of benign prostatic hyperplasia and prostatic carcinoma is an issue that needs to be addressed. (C) 1999 Wiley-Liss, Inc.